Boehringer Ingelheim is preparing to relocate its Australia and New Zealand headquarters to MPark at 15 Khartoum Road, Macquarie Park, Sydney, Australia, while maintaining its long-standing presence in one of Australia’s major health, science and innovation precincts.
The new workplace is expected to become operational before Christmas 2026.
More than a relocation
Boehringer’s Australia and New Zealand management describes the move as an investment in its people, culture and future operating model rather than simply a change of address.
The new headquarters will consolidate the organisation on a single floor and provide dedicated areas for:
-
Collaboration
-
Training
-
Focused work
-
Informal interaction
The company says workplace design was informed by employee feedback and workplace data.
Why Macquarie Park, Sydney matters
Macquarie Park is a major health, science and innovation cluster.
According to the location information cited in the announcement, the precinct generates more than A$13.6 billion in annual economic output and represents one of Australia’s major concentrations of healthcare, science and technology activity.
For a company operating across both human and animal health, remaining within this ecosystem provides proximity to a broad research, technology and talent base.
Animal-health relevance
Boehringer Ingelheim is one of the major global players operating across both human and animal health. The company’s animal-health activities include:
-
Vaccines
-
Parasite control
-
Livestock health
-
Swine health
-
Poultry health
-
Companion-animal therapeutics
-
Veterinary disease prevention
Australia and New Zealand represent strategically important animal-health markets because of their large livestock industries, export-oriented agricultural systems and comparatively sophisticated veterinary infrastructure.
